Orchestra BioMed announces publication of data on effects of AVIM

Orchestra BioMed (OBIO) announced the publication of data in the Journal of the American College of Cardiology: Clinical Electrophysiology from a pressure-volume loop study demonstrating favorable hemodynamic effects of AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension. AVIM therapy is currently being evaluated in the BACKBEAT global pivotal study, which Orchestra BioMed is conducting in collaboration with Medtronic (MDT), to support potential future global regulatory approvals and commercialization of AVIM therapy-enabled devices. The publication, titled “Pressure-Volume Analysis Demonstrates Short- and Long-Term Hemodynamic Effects of Atrioventricular Interval Modulation Therapy in Hypertension,” reports findings from an invasive PV loop analysis in 16 hypertensive pacemaker-indicated subjects, as well as noninvasive PV loop analysis from a subgroup of subjects from the MODERATO II study receiving chronically administered AVIM therapy. The analyses demonstrated that AVIM therapy reduced systolic blood pressure acutely by decreasing cardiac preload and effective arterial elastance unrelated to pacing lead location, while also improving left ventricular end-diastolic and end-systolic volumes. Chronically administered AVIM therapy demonstrated sustained reductions in SBP and end-diastolic volume, indicative of favorable reverse LV remodeling. Results also demonstrated consistently favorable hemodynamic effects using traditional right ventricular and conduction system pacing lead placements.